[1] Wang X, Kruithof-de Julio M, Economides KD, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009;461(7263):495-500.
[2] Iwata T, Schultz D, Hicks J, et al. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One. 2010;5(2):e9427.
[3] Goldstein AS, Huang J, Guo C, et al. Identification of a cell of origin for human prostate cancer. Science. 2010;329(5991): 568-571.
[4] Lawson DA, Zong Y, Memarzadeh S, et al. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A. 2010;107(6):2610-2615.
[5] Maitland NJ, Frame FM, Polson ES, et al. Prostate cancer stem cells: do they have a basal or luminal phenotype. Horm Cancer. 2011;2(1):47-61.
[6] Choy W, Nagasawa DT, Trang A, et al. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme. Neurosurg Clin N Am. 2012;23(3):391-405.
[7] Lee HJ, You DD, Choi DW, et al. Significance of CD133 as a cancer stem cell markers focusing on the tumorigenicity of pancreatic cancer cell lines. J Korean Surg Soc. 2011;81(4): 263-270.
[8] Wang C, Xie J, Guo J, et al. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep. 2012;28(4):1301-1308.
[9] Vander Griend DJ, Karthaus WL, Dalrymple S, et al. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res. 2008;68(23):9703-9711.
[10] Korski K, Malicka-Durczak A, Br?borowicz J. Expression of stem cell marker CD44 in prostate cancer biopsies predicts cancer grade in radical prostatectomy specimens. Pol J Pathol. 2014;65(4):291-295.
[11] Olumi AF, Grossfeld GD, Hayward SW, et al. Carcinoma- associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999;59(19): 5002-5011.
[12] Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005; 65(23):10946-10951.
[13] Taylor RA, Toivanen R, Frydenberg M, et al. Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status. Stem Cells. 2012;30(6):1087-1096.
[14] Goldstein AS, Huang J, Guo C, et al. Identification of a cell of origin for human prostate cancer. Science. 2010;329(5991): 568-571.
[15] Maitland NJ, Frame FM, Polson ES, et al. Prostate cancer stem cells: do they have a basal or luminal phenotype. Horm Cancer. 2011;2(1):47-61.
[16] Lawson DA, Zong Y, Memarzadeh S, et al. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A. 2010;107(6):2610-2615.
[17] Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007;58:267-284.
[18] Morgan TM, Lange PH, Vessella RL. Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci. 2007;12:3000-3009.
[19] Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38(5):696-701.
[20] Reynolds MA, Kastury K, Groskopf J, et al. Molecular markers for prostate cancer. Cancer Lett. 2007;249(1):5-13.
[21] Reynolds MA. Molecular alterations in prostate cancer. Cancer Lett. 2008;271(1):13-24.
[22] Bickers B, Aukim-Hastie C. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era. Anticancer Res. 2009;29(8):3289-3298.
[23] Gong R, Li S. Extraction of human genomic DNA from whole blood using a magnetic microsphere method. Int J Nanomedicine. 2014;9:3781-3789.
[24] Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006;25(12):1696-1708.
[25] Vander Griend DJ, Karthaus WL, Dalrymple S, et al. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res. 2008;68(23):9703-9711.
[26] Tang B, Yoo N, Vu M, et al. Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res. 2007;67(18): 8643-8652.
[27] Mickey DD, Stone KR, Wunderli H, et al. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res. 1977;37(11):4049-4058.
[28] Okada H, Shirakawa T, Miyake H, et al. Establishment of a prostatic small-cell carcinoma cell line (SO-MI). Prostate. 2003;56(3):231-238. |